Sweden’s Medical Products Agency anticipates a continued shortage of estrogen patches and sprays, projecting the situation will not improve until 2027. Despite increased overall sales compared to last year, demand continues to outstrip supply. Maria Wanrud, a group manager at the agency, clarified that while the situation appears dire, more medication is currently being sold than in the previous year. The agency suggests oral tablets as a potential alternative for some women experiencing hormone deficiencies. The prolonged shortage impacts women relying on these specific forms of hormone replacement therapy. Authorities are working to address the supply chain issues, but a swift resolution is not expected. This extended timeframe raises concerns about access to essential medication for affected patients.